Geron Corp
Symbol: GERN (NASDAQ)
1.31
▲ (1.16%) 0.015
Company Description:
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Key Stats
- Today's Open: $1.305
- Today's High: $1.314
- Today's Low: $1.3
- Today's Volume: 1.47K
- Yesterday Close: $1.29
- Yesterday High: $1.36
- Yesterday Low: $1.2735
- Yesterday Volume: 6.91M
- Last Min Volume: 7
- Last Min High: $1.305
- Last Min Low: $1.303
- Last Min VWAP: $1.30486
Company Profile
- Name: Geron Corp
- Website: https://www.geron.com
- Listed Date: 1996-07-31
- Location: FOSTER CITY, CA
- Market Status: Active
- CIK Number: 0000886744
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $823.04M
- Round Lot: 100
- Outstanding Shares: 638.02M
- Asset Type: CS
RECENT FILINGS FOR GERN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 3 | View |
| 2025-08-06 | S-8 | View |
| 2025-08-06 | 8-K | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-01 | 4 | View |
| 2025-06-30 | S-8 | View |
| 2025-05-27 | 8-K | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-13 | 4 | View |
| 2025-05-07 | 10-Q | View |
Latest News on GERN